|
US5030719A
(en)
|
1986-08-28 |
1991-07-09 |
Teijin Limited |
Cytotoxic antibody conjugates and a process for preparation thereof
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP1286700A2
(en)
|
2000-06-01 |
2003-03-05 |
Universite Catholique De Louvain |
Tumor activated prodrug compounds
|
|
CZ2003214A3
(cs)
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
JP4334866B2
(ja)
|
2000-10-09 |
2009-09-30 |
アイシス イノヴェイション リミテッド |
治療用抗体
|
|
GB0100551D0
(en)
|
2001-01-09 |
2001-02-21 |
Queen Mary & Westfield College |
Protein
|
|
US20040109855A1
(en)
|
2002-07-23 |
2004-06-10 |
Herman Waldmann |
Therapeutic antibodies with reduced side effect
|
|
WO2004021861A2
(en)
|
2002-09-03 |
2004-03-18 |
Vit Lauermann |
Targeted release
|
|
US20060024272A1
(en)
|
2004-07-29 |
2006-02-02 |
Large Scale Biology Corporation |
C-terminally truncated interferon
|
|
CN101184771A
(zh)
|
2005-05-26 |
2008-05-21 |
先灵公司 |
干扰素-IgG融合体
|
|
EP1993608A1
(en)
|
2006-03-10 |
2008-11-26 |
Diatos |
Anticancer drugs conjugated to antibody via an enzyme cleavable linker
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
WO2009079837A1
(en)
|
2007-12-18 |
2009-07-02 |
Hangzhou Jiuyuan Gene Engineering Co., Ltd. |
A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
US8734774B2
(en)
|
2010-04-02 |
2014-05-27 |
University Of Rochester |
Protease activated cytokines
|
|
HRP20150664T1
(hr)
|
2010-12-03 |
2015-07-31 |
Adamed Sp. Z O.O. |
Antikancerogeni fuzijski protein
|
|
CA2824515C
(en)
|
2011-01-18 |
2022-09-13 |
Bioniz, Llc |
Compositions and methods for modulating gamma-c-cytokine activity
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
KR20250051130A
(ko)
|
2013-09-25 |
2025-04-16 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
EP3628328B1
(en)
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
GB201411506D0
(en)
|
2014-06-27 |
2014-08-13 |
Univ London Queen Mary |
Modified latency associated protein construct
|
|
PT3215528T
(pt)
|
2014-11-06 |
2019-10-11 |
Hoffmann La Roche |
Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
|
|
IL300408B2
(en)
|
2015-01-20 |
2025-11-01 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
|
|
US20190216898A1
(en)
|
2016-05-06 |
2019-07-18 |
Wang Mulin |
Interleukin Combination and Use Thereof
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
JP2020528878A
(ja)
*
|
2017-06-20 |
2020-10-01 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
がん治療用インターフェロンプロドラッグ
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
US12564632B2
(en)
|
2017-11-08 |
2026-03-03 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
|
CN111954680B
(zh)
|
2017-11-10 |
2024-03-15 |
新加坡科技研究局 |
IL2Rβ/共同γ链抗体
|
|
JP7386161B2
(ja)
|
2017-12-19 |
2023-11-24 |
ブレイズ バイオサイエンス, インコーポレイテッド |
腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
|
|
WO2020113403A1
(en)
|
2018-12-04 |
2020-06-11 |
Beijing Percans Oncology Co. Ltd. |
Cytokine fusion proteins
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
EP3816182A4
(en)
|
2018-05-30 |
2022-07-13 |
Chugai Seiyaku Kabushiki Kaisha |
LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
|
|
CN112351946B
(zh)
|
2018-06-21 |
2022-07-08 |
Tgw物流集团有限公司 |
货仓及拣选系统和用于从悬挂袋和其他装载辅助器具中拣选订单货物的方法
|
|
MX2020014290A
(es)
|
2018-06-22 |
2021-08-05 |
Cugene Inc |
Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
WO2020041758A1
(en)
|
2018-08-24 |
2020-02-27 |
City Of Hope |
Masked cytokine conjugates
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
CA3114179A1
(en)
*
|
2018-09-28 |
2020-04-02 |
Pierre Fabre Medicament |
New immunocytokines for the treatment of cancer
|
|
KR20210080460A
(ko)
|
2018-10-23 |
2021-06-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
이종이량체성 Fc-융합된 단백질
|
|
JP2022512124A
(ja)
|
2018-12-06 |
2022-02-02 |
シートムエックス セラピューティクス,インコーポレイテッド |
マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
|
|
WO2020123980A1
(en)
|
2018-12-14 |
2020-06-18 |
Proviva Therapeutics (Hong Kong) Limited |
Il-15 compositions and methods of use thereof
|
|
CA3136602A1
(en)
|
2019-04-15 |
2020-10-22 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
|
AU2020285636A1
(en)
|
2019-05-24 |
2021-11-04 |
Proviva Therapeutics (Hong Kong) Limited |
IL-2 compositions and methods of use thereof
|
|
EP3981428A4
(en)
|
2019-06-05 |
2023-07-12 |
Chugai Seiyaku Kabushiki Kaisha |
Protease substrate, and polypeptide including protease cleavage sequence
|
|
CN114341189A
(zh)
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|
|
KR20260089650A
(ko)
|
2019-07-12 |
2026-06-15 |
프로비바 테라퓨틱스 (홍콩) 리미티드 |
Il-2 조성물 및 이의 사용 방법
|
|
AU2020316002B2
(en)
|
2019-07-25 |
2026-05-07 |
The University Of Chicago |
Compositions and methods comprising protease-activated therapeutic agents
|
|
EP4004026A4
(en)
|
2019-07-25 |
2023-11-15 |
Trutino Biosciences Inc. |
IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
|
|
EP4013775A1
(en)
|
2019-08-12 |
2022-06-22 |
Askgene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
|
EP4017594A1
(en)
|
2019-08-21 |
2022-06-29 |
Askgene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
WO2021062406A1
(en)
|
2019-09-28 |
2021-04-01 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
WO2021113577A1
(en)
|
2019-12-05 |
2021-06-10 |
Immune Targeting Inc. |
Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
|
|
AU2020403148A1
(en)
|
2019-12-13 |
2022-06-30 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
US20240043489A1
(en)
|
2020-01-15 |
2024-02-08 |
Trutino Biosciences Inc. |
Cytokine Prodrugs Comprising a Cleavable Linker
|
|
MX2022011676A
(es)
|
2020-03-23 |
2023-03-08 |
Zymeworks Bc Inc |
Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
|
|
US20230226202A1
(en)
|
2020-03-30 |
2023-07-20 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il15 compositions and methods of use thereof
|
|
PH12022552627A1
(en)
|
2020-04-01 |
2023-01-04 |
Xilio Dev Inc |
Masked il-2 cytokines and their cleavage products
|
|
PH12022552630A1
(en)
|
2020-04-01 |
2023-01-04 |
Xilio Dev Inc |
Masked il-15 cytokines and their cleavage products
|
|
BR112022019708A2
(pt)
*
|
2020-04-01 |
2022-12-20 |
Xilio Dev Inc |
Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
|
|
AU2021254283B2
(en)
|
2020-04-10 |
2025-12-11 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
CN115996946A
(zh)
|
2020-04-30 |
2023-04-21 |
免疫靶向有限公司 |
可活化il2组合物和使用方法
|
|
CA3178657A1
(en)
|
2020-05-19 |
2021-11-25 |
William Winston |
Activatable il-12 polypeptides and methods of use thereof
|